
Please try another search
YTD | 3M | 1Y | 3Y | 5Y | 10Y | |
---|---|---|---|---|---|---|
Growth of 1000 | 1010 | 997 | 1051 | 1240 | 1537 | 2249 |
Fund Return | 1% | -0.27% | 5.14% | 7.43% | 8.97% | 8.44% |
Place in category | 1640 | 1690 | 1777 | 1370 | 1126 | 293 |
% in Category | 87 | 89 | 98 | 89 | 86 | 47 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Manulife Glbl Eq Cl Sr Adv | 7.26B | 1.00 | 7.44 | 8.45 | ||
Manulife Glbl Eq Cl Sr F | 7.26B | 1.20 | 8.76 | 9.80 | ||
Manulife Glbl Eq Cl Sr FT6 | 7.26B | 1.20 | 8.77 | 9.80 | ||
Manulife Div incm Fd Sr Adv | 6.58B | 1.45 | 6.72 | 8.42 | ||
Manulife Div incm Fd Sr F | 6.58B | 1.64 | 7.92 | 9.64 |
Name | Rating | Total Assets | YTD% | 3Y% | 10Y% | |
---|---|---|---|---|---|---|
Fidelity Global Innovators Class F | 17.07B | -0.93 | 23.49 | - | ||
Capital Group Glbal Equity Fd F CAD | 13.18B | 2.07 | 11.83 | 10.97 | ||
Capital Group Glbal Equity Fd A CAD | 13.18B | 1.89 | 10.61 | 9.74 | ||
Capital Group Glbal Equity Fd D CAD | 13.18B | 2.03 | 11.47 | 10.50 | ||
EdgePoint Global Portfolio Series F | 12.47B | 6.10 | 9.90 | 8.83 |
Name | ISIN | Weight % | Last | Change % | |
---|---|---|---|---|---|
Publicis Groupe | FR0000130577 | 5.19 | 90.00 | -0.22% | |
Marsh McLennan | US5717481023 | 4.43 | 242.39 | -0.42% | |
Alphabet C | US02079K1079 | 4.14 | 156.06 | -4.89% | |
Microsoft | US5949181045 | 4.14 | 378.80 | -3.02% | |
UnitedHealth | US91324P1021 | 3.93 | 516.04 | +0.06% |
Type | Daily | Weekly | Monthly |
---|---|---|---|
Moving Averages | Strong Sell | Strong Sell | Sell |
Technical Indicators | Strong Sell | Strong Sell | Sell |
Summary | Strong Sell | Strong Sell | Sell |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review